The ClearCoast™ Magnetic Resonance Outcome PMS Study

Breast Cancer Clinical Trial

Official title:

The ClearCoast™ Magnetic Resonance Outcome Post Marketing Surveillance Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05458739
• Other study ID #: 735CLD Rev.04
• Status: Recruiting
• Start date: June 24, 2021
• Est. completion date: January 1, 2025

Study information

• Verified date: February 2023
• Source: Clear Cut Medical Ltd.
• Contact: Anna Levin
• Phone: +972-8-6326004
• Email: alevin[@]clrcut.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Post Marketing Surveillance (PMS) study. Up to 93 patients undergoing breast conserving surgery will be enrolled in a prospective, single center, non-randomized controlled study, and a corresponding number of historical patients that underwent BCS will serve as the historical control group, accounting for a 1:1 ratio. All study patients and the patients in the historical control group will be required to meet the study eligibility criteria. BCS will be performed with the routine standard of care (SOC), including intra-operative methods used to improve margin assessment. In addition to SOC process, the main specimen from patients found eligible will be scanned in the ClearCoast™ system. The surgeon will utilize the information from the ClearCoast images in his margin assessments evaluation which includes the diffusion at the surface of a particular aspect (suggesting irregular tissue at the specimen's surface), and decide whether to excise additional tissue. The decision-making process including MR images interpretation and the surgical decisions will be evaluated and documented. Following procedure, routine histopathology examination will be performed accompanied by the ClearCoast optical and parametric maps. This study is a controlled design, in which subjects previously having undergone BCS by the same surgeons, will serve as the historical control group, comparing the following endpoints: - Complete surgical re-excision rate - Total excised breast tissue volume The study Control group is composed of historical data from patients previously undergone BCS, under the same site SOC surgical practice, practicing surgeons, and study eligible criteria. This allows reducing inter-group variability and bias. A device operator trained by ClearCut Medical will operate the device throughout the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 93
• Est. completion date: January 1, 2025
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Women histologically diagnosed with invasive and/or in situ carcinoma of the breast, undergoing primary lumpectomy (partial mastectomy) procedure

2. Age =18

3. Patient is willing and capable to provide written Informed Consent Form (ICF)

Exclusion Criteria:

4. Prior surgical procedure in the same breast within 12 months prior to the surgery date

5. Recurrent breast cancer surgery

6. Neoadjuvant chemotherapy and/or neoadjuvant hormone therapy

7. Previous radiation therapy in the operated breast

8. Pregnancy

9. Lactation

10. Patient has subglandular breast implants in the operated breast

11. moribund patient and/or patient with comorbidities, per principal investigator discretion

12. Participating in any other investigational study for either drug or device which might influence collection of valid data under this study.

Intraoperative:

13. Specimen undergoing pathological specimen assessment (e.g. by frozen section, imprint cytology or gross assessment by sectioning), resulting in deformation of specimen shape/tissue properties (e.g. Formalin conservation)

14. Specimen dimension is larger than the Tissue container volume (200cc)

15. Inability to define aspect color/orientation and/or margin border

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Device:
• ClearCoast MR System
The removed specimen is scanned using the ClearCoast MR System.

Locations

Country	Name	City	State
Germany	Agaplesion Markus Krankenhaus	Frankfurt
United Kingdom	Western General Hospital , Breast Unit	Edinburgh	Scotland

Sponsors (1)

Lead Sponsor	Collaborator
Clear Cut Medical Ltd.

Countries where clinical trial is conducted

Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ClearCoast™ Success rate	the success of the ClearCoast™ system indicating abnormal margins of breast tissue specimen intra-operatively.; This endpoint compares the proportion of patients that undergo a re-excision surgery following the primary lumpectomy procedure between the two groups.	6 months
Secondary	Secondary Outcome - Re-excision rate	Comparing the percentage of positive margins (%) of the main specimen (as detected by post-operative microscopically as having cancer within 1mm or less of the inked surface) and document which of those positive margins have been addressed by intra-operative re-excision or the absence of further tissue to be re-excised (e.g., undermining the skin or reaching the pectoralis fascia).	1 year